Navigation Links
Prostate cancer study proves drug delays disease progression
Date:1/23/2012

(TORONTO, Canada Jan. 24, 2012) For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride ("Avodart") delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network (UHN).

The findings are published online today in The Lancet. "The results prove that using active surveillance plus dutasteride is a viable, safe and effective treatment option for men who often undergo aggressive local treatment despite low risk of dying from the disease," says Dr. Fleshner, a surgical oncologist in UHN's Princess Margaret Cancer Program and Professor of Surgery at the University of Toronto. Dr. Fleshner also holds the Love Chair in Prostate Cancer Prevention Research.

"This is very good news for men with low-risk disease because aggressive treatment can have a major impact on their quality of life, with risks of impotence and incontinence," says Dr. Fleshner.

The three-year clinical trial enrolled 302 men between the ages of 48 and 82 diagnosed with low-risk localized prostate cancer and regularly monitored for clinical changes a treatment option called "active surveillance". In the trial known as REDEEM (REduction by Dutasteride of clinical progression Events in Expectant Management of prostate cancer) participants were randomized 1:1 to receive dutasteride or a matching placebo daily. The men also underwent biopsies at 1.5 and three years.

The study showed a significant delay in disease progression in the men treated with dutasteride 36% compared with 23% who received the placebo. As well, the final biopsies showed the men treated with the drug were less likely to have cancer detected 36% compared with 31%.

"This is the first study to show that a 5a-reductase inhibitor such as dutasteride reduces the need for aggressive treatment in low-risk disease," says Dr. Fleshner. "The drug, currently commonly used to treat enlarged prostate, works by inhibiting the male sex hormone that causes the enlargement in the first place."

Dr. Fleshner says a small percentage of men reported drug-related side effects including sexual difficulty with either desire or erections (5%), or breast tenderness or enlargement (3%). "It's important to realize that these drugs have been around for almost 20 years in clinical practice to treat enlarged prostates and so we have a wealth of knowledge about their side effects, which are reversible if the drug is stopped."

Participants were also assessed for cancer-related anxiety and the men on dutasteride reported feeling much less anxious because their biopsies and PSA values improved, adds Dr. Fleshner. (PSA or prostate-specific antigen is a blood test used to help diagnose prostate cancer.)

The Canadian Cancer Society estimates 25,500 new cases of prostate cancer will be diagnosed this year and that 4,100 men will die from the disease.


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.ca
416-946-2846
University Health Network
Source:Eurekalert

Related medicine news :

1. Eating smart: Researcher studies foods, dietary supplements that may reduce risk of prostate cancer
2. Cabazitaxel with radiation and hormone therapy may improve prostate cancer survival
3. Music May Ease Anxiety, Pain in Prostate Biopsy Patients
4. UNC scientists collaborate to find first major genetic mutation associated with hereditary prostate cancer risk
5. Scientists Identify Inherited Prostate Cancer Gene
6. Headphone music eases anxiety during prostate biopsies
7. PSA Test for Prostate Cancer Doesnt Save Lives: Study
8. Mass prostate cancer screening doesnt reduce deaths
9. Proton therapy effective prostate cancer treatment
10. PSA testing, combined with other relevant patient data can reduce unnecessary prostate biopsies
11. Panel endorses active monitoring and delay of treatment for low-risk prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... DC (PRWEB) , ... April 24, 2017 , ... The ... recognized during ATA 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, on ... Santana Telehealth Project for using telemedicine to improve the lives of the poor and ...
(Date:4/24/2017)... IL (PRWEB) , ... April 24, 2017 , ... Today, Bright Pink , a ... in young women, names a new CEO. , Bright Pink is proud to announce ... she would be moving to a new role as Chairman of the Board and ...
(Date:4/24/2017)... Raton, Florida (PRWEB) , ... April 24, 2017 ... ... develops a variety of unique liquid food supplements, announced its popular products are ... nutritional products. , ALP Nutrition® prioritizes the use of premium natural ingredients ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... ... (CDC), rising prescription opioid overdose deaths now claim the lives of 62 Americans ... civil case filings against drug manufacturers, distributors, pharmacies and prescribers by more than ...
(Date:4/24/2017)... ... 24, 2017 , ... As a former supermodel known for her timeless beauty, ... for single women is that she put all the words in her new book, ... insight, personal experiences and sparkling sense of humor have inspired her to write a ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... , April 20, 2017 Research and ... Pharmaceutical Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), ... Forecasts, 2014 - 2025" report to their offering. ... The Latin American pharmaceutical ... billion by 2025 Low drug registration cost in ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
Breaking Medicine Technology: